Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Bluebird, Vertex Gene Therapies May Answer $1m Question: Can Competition Reduce Rx Prices?

09 Dec 2023

• By Cathy Kelly

Bluebird May Need To Buckle Up For A Bumpy Ride • Source: Shutterstock

Related Content

Gene Therapy: US FDA Labeling For Vertex’s Casgevy, Bluebird’s Lyfgenia Reflect Different Risks

09 Dec 2023

Lack Of Competition Equals Higher Drug Prices: HHS Analysis Is Slogan In Search Of Solutions

08 Dec 2023

Medicaid Outcomes-Based Payment Model For Cell, Gene Therapy to Launch In 2025

13 Oct 2023

As Sickle Cell Gene Therapies Move To Market, Health Inequities Could Help Pricing Debate

11 Aug 2023

Related Companies

Vertex Pharmaceuticals Incorporated

CRISPR Therapeutics AG

Bluebird Bio

Additional Topics

United States Reimbursement Gene Therapy Pricing Debate Policy Pricing Strategies Medicaid BioPharmaceutical Blood & Coagulation Disorders

More from Market Access

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.